33 related articles for article (PubMed ID: 38609108)
1. (NDMA) METFORMIN AND (NTTP) SITAGLIPTIN INDUCED CUTANEOUS MELANOMAS: LINKS TO NITROSOGENESIS, NITROSO-PHOTOCARCINOGENESIS, ONCOPHARMACOGENESIS AND THE METABOLIC REPROGRAMMING.
Tchernev G; Broshtilova V
Georgian Med News; 2024 Mar; (348):132-143. PubMed ID: 38807407
[TBL] [Abstract][Full Text] [Related]
2. METASTATIC NODULAR MELANOMA DEVELOPING ON NEVUS SPILUS DURING INTAKE OF BETA BLOCKERS (BISOPROLOL/NEBIVOLOL) AND ACE INHIBITORS (PERINDOPRIL). POTENTIAL LINKS TО THE DRUG RELATED NITROSOGENESIS/CARCINOGENESIS, DUNNING-KRUGER EFFECT AND GENETIC WEAPONS OF THE NEW GENERATION.
Tchernev G
Georgian Med News; 2023 Oct; (343):172-178. PubMed ID: 38096536
[TBL] [Abstract][Full Text] [Related]
3. MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
Tchernev G; Naydekova N
Georgian Med News; 2023 Nov; (344):152-158. PubMed ID: 38236117
[TBL] [Abstract][Full Text] [Related]
4. NITROSOGENESIS OF CUTANEOUS MELANOMA: SIMULTANEOUSLY DEVELOPMENT OF PRIMARY CUTANEOUS THICK MELANOMA OF THE BREAST, THIN MELANOMA/DYSPLASTIC MOLE OF THE BACK DURING PARALLEL INTAKE OF BISOPROLOL, AMLODIPINE AND VALSARTAN/ HCT: NITROSAMINE POLYCONTAMINATION IN THE MULTIMEDICATION AS THE MOST POWERFUL SKIN CANCER TRIGGER.
Tchernev G
Georgian Med News; 2023 Jun; (339):83-88. PubMed ID: 37522780
[TBL] [Abstract][Full Text] [Related]
5. PERIOCULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.
Tchernev G; Dimova D
Georgian Med News; 2024 Feb; (347):70-76. PubMed ID: 38609117
[TBL] [Abstract][Full Text] [Related]
6. NITROSOGENESIS LESSONS FROM DERMATOLOGISTS-NITROSAMINES/ NDSRIS CONTAMINATION OF THE POLIMEDICATION IN POLIMORBID PATIENTS AS THE MOST POWERFUL SKIN CANCER INDUCTOR: DOUBLE HATCHET FLAP FOR SCC OF THE SCALP OCCURRING DURING TREATMENT WITH VALSARTAN/ HYDROCHLOROTHIAZIDE AND LERCANIDIPINE.
Tchernev G
Georgian Med News; 2023 Sep; (342):74-79. PubMed ID: 37991960
[TBL] [Abstract][Full Text] [Related]
7. DRUG RELATED NITROSOGENESIS, PHOTOCARCINOGENESIS AND ONCOPHARMACOGENESIS OF NODULAR MELANOMA: A CASE RELATED ANALYSIS CONCERNING THE POLYCONTAMINATION OF THE POLYMEDICATION WITH VALSARTAN/HYDROCHLOROTHIAZIDE AND BISOPROLOL.
Tchernev G; Broshtilova V; Ivanov L; Alexandrov A; Smilov N; Kordeva S
Georgian Med News; 2024 Feb; (347):24-27. PubMed ID: 38609108
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature.
Tchernev G; Bitolska A; Patterson JW
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1075-1080. PubMed ID: 34085580
[No Abstract] [Full Text] [Related]
9. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
10. The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis.
Heisel AGU; Vuurboom MD; Daams JG; de Rie MA; Vogt L; van den Born BH; Olde Engberink RHG
Vascul Pharmacol; 2023 Jun; 150():107173. PubMed ID: 37084802
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
[TBL] [Abstract][Full Text] [Related]
12. [Hydrochlorothiazide and skin cancer].
Olde Engberink RHG; van der Hoeven NV; Zwinderman AH; van den Born BH
Ned Tijdschr Geneeskd; 2019 May; 163():. PubMed ID: 31120217
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
